RDC (Radionuclide Drug Conjugate), a novel trend in bioconjugation drug development, has multiple uses in clinical diagnostic and treatment. Four components are needed in RDC, including radionuclide, chelator, linker, and delivery part. Three kinds of delivery parts, including antibodies, small molecules, and peptides are utilized in RDC.